Nektar Therapeutics announced the existence of a collaboration with Roche under which Nektar has licensed a proprietary PEG (PEGylation) reagent used in the manufacture of Roche's product CERA (Continuous Erythropoiesis Receptor Activator). Under the three-year old collaboration, Nektar receives milestone and manufacturing revenues during development and will receive royalty and manufacturing revenues upon successful commercialization of the product.

Nektar Therapeutics provides industry-leading drug delivery technologies, expertise and manufacturing to enable the development of high-value, differentiated therapeutics.